Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CG 5503; tapentadol · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| CG 5503;tapentadol | DRUG | - |
Inclusion Criteria: * A clinical diagnosis of one of the following: low-back pain of non-malignant origin for at least 3 months, osteoarthritis of the knee or hip for at least 3 months * require daily doses of analgesia medication for chronic pain that is consistent with or makes them candidates fo...
CG 5503, also known as tapentadol, is an investigational small molecule being studied for the treatment of osteoarthritis. It is being developed for chronic pain conditions, including osteoarthritis, pain intensity assessment, arthralgia, sciatica, and low back pain.
CG 5503, or tapentadol, is a small molecule in clinical development for osteoarthritis. The specific molecular target of CG 5503 has not been disclosed in the available information.
CG 5503, also known as tapentadol, is being developed by Johnson & Johnson (NYSE: JNJ). The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for chronic pain conditions.
CG 5503, or tapentadol, is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed, evaluating its safety in patients with chronic pain.
CG 5503, also known as tapentadol, has one completed Phase 3 clinical trial (NCT00364546). This study evaluated the 90-day safety of tapentadol immediate release compared to oxycodone immediate release in 877 patients with chronic pain, including osteoarthritis.
Yes, CG 5503 is the same as tapentadol. The drug is referred to by both names in clinical research. It is being developed by Johnson & Johnson for the treatment of chronic pain conditions, including osteoarthritis.